

## 12-8075: Anti-Human IL 12/23 (Briakinumab) DyLight® 488

<b>Clonality :</b>	Monoclonal
<b>Clone Name :</b>	ABT-874
<b>Application :</b>	Functional Assay
<b>Reactivity :</b>	Human
<b>Alternative Name :</b>	IL-12p40; Interleukin 12; Interleukin 23; IL12; IL23; IL-12; IL-23
<b>Isotype :</b>	Human IgG1lambda
<b>Immunogen Information :</b>	This antibody was produced by phage display technology.

### Description

Expression Host : HEK-293

This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Briakinumab. Briakinumab recognizes both human IL12 and IL23 via IL-12/23p40. This product is for research use only. Briakinumab is a human monoclonal antibody targets the p40 subunit shared by interleukins 12 and 23. IL-12 associates with IL-23alpha to form the heterodimeric cytokine IL-23. IL-23 is associated with various autoimmune inflammatory diseases, and is particularly highly expressed in psoriasis skin lesions. In addition, IL-23 is suspected to play a role in tumorigenesis. Briakinumab binds to and neutralizes human IL-12 and IL-23 (via their shared p40 subunit) and is being investigated for the treatment of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. Anti-Human IL 12/23 (Briakinumab) utilizes the same variable regions from the therapeutic antibody Briakinumab making it ideal for research projects.

### Product Info

<b>Amount :</b>	100 µg Concentration : 0.2 mg/ml
<b>Content :</b>	This DyLight® 488 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
<b>Storage condition :</b>	This DyLight® 488 conjugate is stable when stored at 2-8°C. Do not freeze.

### Application Note

The suggested concentration for Briakinumab biosimilar antibody for staining cells in flow cytometry is  $\leq 1.0$  µg per 10<sup>6</sup> cells in a volume of 100 µl. Titration of the reagent is recommended for optimal performance for each application.